Clinical Case Studies

An elderly woman with history of asbestos exposure and pleural mesothelioma that was treated with left-sided pleurodesis presented with chest pain and respiratory distress. This case demonstrates how Biograph Vision Quadra™ achieves a 5-minute, low-dose, single-bed, whole-body ¹⁸F-FDG PET/CT to help delineate predominantly pericardial involvement in recurrent pleural mesothelioma.

An elderly woman with history of ovarian carcinoma underwent PET/CT evaluation. This case demonstrates how Biograph Vision Quadra™ was utilized to achieve a 5-minute, low-dose, single-bed, whole-body ¹⁸F-FDG PET/CT to help delineate peritoneal carcinomatosis in ovarian carcinoma.

An approximately 65-year-old female with metastatic breast cancer underwent sequential ¹⁸F-FES and ¹⁸F-FDG PET/CT imaging on Biograph Vision™ PET/CT to assess the extent of disease and estrogen-receptor (ER) status. This case demonstrates the utility of ¹⁸F-FES PET/CT in the evaluation of metastatic disease burden to help inform therapy treatment planning.

An elderly female with history of a primary intestinal neuroendocrine tumor (NET) and suspicion of recurrence was referred for PET/CT staging to evaluate suspected metastases. This case demonstrates how Biograph Vision Quadra™ PET/CT was utilized to achieve fast, low-dose, single-bed, whole-body ¹⁸F-SiFAlin-TATE PET/CT delineation of neuroendocrine tumor metastases.

A male in his 70s with a history of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) underwent routine ⁶⁸Ga-PSMA-11 PET/CT imaging on Biograph mCT Flow™ PET/CT. ⁶⁸Ga-PSMA-11 PET/CT findings confirmed PSMA expression in the metastatic disease, which qualified the patient for ¹⁷⁷Lu-PSMA-617 treatment. The patient received ¹⁷⁷Lu-PSMA-617 therapy followed by fast, multi-bed, quantitative SPECT/CT imaging after each treatment cycle. This clinical case demonstrates how Symbia Intevo Bold™ with xSPECT Quant™ enables ¹⁷⁷Lu-PSMA-617 treatment response assessment.

Three patients with metastatic prostate cancer underwent sequential, quantitative SPECT/CT on Symbia™ SPECT/CT following a single dose of albumin-bound ¹⁷⁷Lu PSMA-ALB-56. This case series demonstrates the utility of sequential, quantitative SPECT/CT in obtaining accurate time activity curves (TACs) for subsequent dosimetry, which is of key importance for improving therapeutic outcomes while avoiding toxicity.

A 62-year-old female with atypical chest pain and a history of major factors for coronary artery disease (CAD) underwent a ⁸²Rb PET/CT myocardial perfusion study on a Biograph Vision™ PET/CT scanner. This case demonstrates the value of ⁸²Rb myocardial perfusion PET/CT and blood flow estimation in the delineation of multivessel CAD and post-therapy stent occlusion.

An approximately 75-year-old female presenting with a history of bilateral total knee arthroplasty (TKA) and pain in both knees underwent a ^99mTc HMDP bone study on Symbia Pro.specta™ SPECT/CT. This case highlights the clinical utility of xSPECTTM technologies with iterative metal artifact reduction (iMAR) in the detection of TKA prosthetic loosening.

An approximately 75-year-old male with history of posterior spinal stabilization surgery and severe lower back pain underwent a ^99mTc MDP bone study on Symbia Pro.specta™ SPECT/CT to determine the site of bone stress and related pathology. This case illustrates ^99mTc MDP bone SPECT/CT imaging in the evaluation of pain following thoracolumbar spinal fusion surgery.

An approximately 70-year-old female with bilateral femoral intramedullary prostheses presenting with severe pain and slight wound discharge underwent a ^99mTc HMPAO-labeled leukocyte study on Symbia Pro.specta™ SPECT/CT. This case demonstrates the value of using SPECT/CT with radiolabeled leukocytes and iterative metal artifact reduction (iMAR) in the evaluation of bony and prosthetic joint pathologies.

An elderly male with a neuroendocrine tumor (NET) and liver metastases underwent sequential SPECT/CT on Symbia Pro.specta™ SPECT/CT following a therapy dose of ¹⁷⁷Lu DOTATATE. This case demonstrates the value of using xSPECT Quant™ for the reproducible quantification of tracer concentration, which is instrumental for accurate dosimetry.

A 74-year-old male with a primary duodenal tumor underwent ⁶⁸Ga DOTATATE PET/CT staging. This case demonstrates the role of the Biograph Vision Quadra™ in the evaluation of somatostatin-receptor density within neuroendocrine tumor metastases to help define metastatic burden and inform radionuclide therapy planning.

A 75-year-old male with diffuse large B-cell lymphoma underwent PET/CT imaging on a Biograph mCT Flow™ scanner to assess residual disease. The patient was referred for COVID-19 testing due to suspicious hypermetabolic parenchymal foci in the lungs. This case reviews PET/CT in a differential diagnosis of COVID-19 within incidental findings.

A 75-year-old female with recurrent metastatic invasive lobular breast cancer underwent concurrent ¹⁸F FDG PET/CT and ¹⁸F FES PET/CT imaging to evaluate the extent of estrogen receptor (ER)-positive osseous lesions. This case highlights the use of ¹⁸F FES PET/CT in the evaluation of ER-positive breast cancer when ¹⁸F FDG PET/CT findings are inconclusive.